Nearly a dozen advocacy groups have complained to Congress that a recent Department of Commerce draft report that offered ways to modernize technology transfer and innovation would limit the ability of the federal government to curb “excessive” prescription drug prices.

The 135-page report, which was issued last December by the department’s National Institute of Standards and Technology, broadly addresses innovation and proposes various suggestions for maximizing returns on taxpayer investment in R&D.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy